Comparative examination of Hb-maintenance dose and cost effectiveness between darbepoetin and recombinant human erythropoietin in hemodialysis patients: a prospective study
-
- Ogata Ryouji
- Suzuki-Nephro Clinic The Third Department of Internal Medicine, Faculty of Medicine, The University of Yamanashi
-
- Osada Kazumoto
- Suzuki-Nephro Clinic
-
- Takei Katsuya
- Suzuki-Nephro Clinic
-
- Yamoto Yuka
- Suzuki-Nephro Clinic
-
- Furuya Akemi
- Suzuki-Nephro Clinic
-
- Inoue Hironobu
- The Third Department of Internal Medicine, Faculty of Medicine, The University of Yamanashi
-
- Haraguchi Kazutaka
- The Third Department of Internal Medicine, Faculty of Medicine, The University of Yamanashi
-
- Suzuki Hikohito
- Suzuki-Nephro Clinic
-
- Kobayashi Tetsuro
- The Third Department of Internal Medicine, Faculty of Medicine, The University of Yamanashi
Bibliographic Information
- Other Title
-
- 血液透析患者に対するＨｂ維持量および費用対効果からみたｄａｒｂｅｐｏｅｔｉｎとｒＨｕＥＰＯの比較検討（前向き介入試験）
- ケツエキ トウセキ カンジャ ニ タイスル Hb イジリョウ オヨビ ヒヨウ タイ コウカ カラ ミタ darbepoetin ト rHuEPO ノ ヒカク ケントウ マエムキ カイニュウ シケン
Search this article
Abstract
In patients with end-stage renal disease, renal anemia develops as a result of erythropoietin deficiency. Recombinant human erythropoietin (rHuEPO) has been widely prescribed to treat renal anemia. Darbepoetin, which is an analogue of rHuEPO with an increased terminal half-life, has been approved in Japan since July 2007. We performed a prospective study to compare Hb-maintenance dose and cost effectiveness between darbepoetin and rHuEPO in hemodialysis patients for 18 weeks. Our cohort comprised 77 patients who were undergoing maintenance hemodialysis 3 times per week in Suzuki-Nephro Clinic. The patients were divided into two groups. Thirty-nine patients were assigned to receive rHuEPO 750IU/HD and 39 patients were assigned darbepoetin 15μg/week as Hb-maintenance dose to maintain a target Hb level of 10.0 to 11.4g/dL, respectively. At 18 weeks, the mean Hb level of darbepoetin group was significantly higher than that of rHuEPO group. The proportion of patients whose Hb level exceeded target Hb level was significantly higher in the darbepoetin group than rHuEPO group. Although final Hb level was higher in darbepoetin group than that of rHuEPO group, the cost was lower in the darbepoetin group than in the rHuEPO group, indicating that darbepoetin was definitely superior to rHuEPO in cost effectiveness. The present results suggests that the dose of darbepoetin 15μg/week is high as a regular dose to maintain the target Hb level in hemodialysis patients and it may be necessary to reduce the dose to less than 15μg/week.
Journal
-
- Nihon Toseki Igakkai Zasshi
-
Nihon Toseki Igakkai Zasshi 41 (12), 837-842, 2008
The Japanese Society for Dialysis Therapy
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679654568064
-
- NII Article ID
- 10023974491
-
- NII Book ID
- AN10432053
-
- ISSN
- 1883082X
- 13403451
-
- NDL BIB ID
- 9760800
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed